FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382775265> ?p ?o ?g. }

• W4382775265 abstract "Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a subset of patients will develop resistance to ADTs and the tumors will transition to castration-resistant prostate cancer (CRPC). Second generation hormonal therapies such as abiraterone acetate and enzalutamide are typically given to men with CRPC. However, these treatments are not curative and typically prolong survival only by a few months. Several resistance mechanisms contribute to this lack of efficacy such as the emergence of AR mutations, AR amplification, lineage plasticity, AR splice variants (AR-Vs) and increased kinase signaling. Having identified SRC kinase as a key tyrosine kinase enriched in CRPC patient tumors from our previous work, we evaluated whether inhibition of SRC kinase synergizes with enzalutamide or chemotherapy in several prostate cancer cell lines expressing variable AR isoforms. We observed robust synergy between the SRC kinase inhibitor, saracatinib, and enzalutamide, in the AR-FL+/AR-V+ CRPC cell lines, LNCaP95 and 22Rv1. We also observed that saracatinib significantly decreases AR Y 534 phosphorylation, a key SRC kinase substrate residue, on AR-FL and AR-Vs, along with the AR regulome, supporting key mechanisms of synergy with enzalutamide. Lastly, we also found that the saracatinib-enzalutamide combination reduced DNA replication compared to the saracatinib-docetaxel combination, resulting in marked increased apoptosis. By elucidating this combination strategy, we provide pre-clinical data that suggests combining SRC kinase inhibitors with enzalutamide in select patients that express both AR-FL and AR-Vs." @default.
• W4382775265 created "2023-07-02" @default.
• W4382775265 creator A5023804206 @default.
• W4382775265 creator A5025141753 @default.
• W4382775265 creator A5033796700 @default.
• W4382775265 creator A5034691008 @default.
• W4382775265 creator A5046292926 @default.
• W4382775265 creator A5049481020 @default.
• W4382775265 creator A5062157317 @default.
• W4382775265 creator A5065318155 @default.
• W4382775265 date "2023-06-30" @default.
• W4382775265 modified "2023-10-10" @default.
• W4382775265 title "Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC" @default.
• W4382775265 cites W1506601011 @default.
• W4382775265 cites W1575345943 @default.
• W4382775265 cites W1772185780 @default.
• W4382775265 cites W1967789049 @default.
• W4382775265 cites W1975120553 @default.
• W4382775265 cites W1984373702 @default.
• W4382775265 cites W1996776596 @default.
• W4382775265 cites W2024648144 @default.
• W4382775265 cites W2046837085 @default.
• W4382775265 cites W2055013229 @default.
• W4382775265 cites W2057472767 @default.
• W4382775265 cites W2059286602 @default.
• W4382775265 cites W2074429860 @default.
• W4382775265 cites W2078400569 @default.
• W4382775265 cites W2080748037 @default.
• W4382775265 cites W2085847636 @default.
• W4382775265 cites W2087998073 @default.
• W4382775265 cites W2091926537 @default.
• W4382775265 cites W2096439168 @default.
• W4382775265 cites W2105762010 @default.
• W4382775265 cites W2111047881 @default.
• W4382775265 cites W2117905749 @default.
• W4382775265 cites W2119504728 @default.
• W4382775265 cites W2128628205 @default.
• W4382775265 cites W2131296758 @default.
• W4382775265 cites W2142100128 @default.
• W4382775265 cites W2146391441 @default.
• W4382775265 cites W2148643283 @default.
• W4382775265 cites W2156215080 @default.
• W4382775265 cites W2165846310 @default.
• W4382775265 cites W2171020858 @default.
• W4382775265 cites W2179438025 @default.
• W4382775265 cites W2195725578 @default.
• W4382775265 cites W2402183197 @default.
• W4382775265 cites W2419426348 @default.
• W4382775265 cites W2494960642 @default.
• W4382775265 cites W2806440020 @default.
• W4382775265 cites W2892078335 @default.
• W4382775265 cites W2897146989 @default.
• W4382775265 cites W2949193973 @default.
• W4382775265 cites W2966606200 @default.
• W4382775265 cites W3209637856 @default.
• W4382775265 cites W4226211056 @default.
• W4382775265 cites W4254687493 @default.
• W4382775265 doi "https://doi.org/10.3389/fonc.2023.1210487" @default.
• W4382775265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37456235" @default.
• W4382775265 hasPublicationYear "2023" @default.
• W4382775265 type Work @default.
• W4382775265 citedByCount "0" @default.
• W4382775265 crossrefType "journal-article" @default.
• W4382775265 hasAuthorship W4382775265A5023804206 @default.
• W4382775265 hasAuthorship W4382775265A5025141753 @default.
• W4382775265 hasAuthorship W4382775265A5033796700 @default.
• W4382775265 hasAuthorship W4382775265A5034691008 @default.
• W4382775265 hasAuthorship W4382775265A5046292926 @default.
• W4382775265 hasAuthorship W4382775265A5049481020 @default.
• W4382775265 hasAuthorship W4382775265A5062157317 @default.
• W4382775265 hasAuthorship W4382775265A5065318155 @default.
• W4382775265 hasBestOaLocation W43827752651 @default.
• W4382775265 hasConcept C108636557 @default.
• W4382775265 hasConcept C121608353 @default.
• W4382775265 hasConcept C126322002 @default.
• W4382775265 hasConcept C134018914 @default.
• W4382775265 hasConcept C143998085 @default.
• W4382775265 hasConcept C170493617 @default.
• W4382775265 hasConcept C184235292 @default.
• W4382775265 hasConcept C2776551883 @default.
• W4382775265 hasConcept C2777899217 @default.
• W4382775265 hasConcept C2780192828 @default.
• W4382775265 hasConcept C2781190966 @default.
• W4382775265 hasConcept C2908647359 @default.
• W4382775265 hasConcept C502942594 @default.
• W4382775265 hasConcept C61367390 @default.
• W4382775265 hasConcept C71924100 @default.
• W4382775265 hasConcept C86803240 @default.
• W4382775265 hasConcept C95444343 @default.
• W4382775265 hasConcept C99454951 @default.
• W4382775265 hasConceptScore W4382775265C108636557 @default.
• W4382775265 hasConceptScore W4382775265C121608353 @default.
• W4382775265 hasConceptScore W4382775265C126322002 @default.
• W4382775265 hasConceptScore W4382775265C134018914 @default.
• W4382775265 hasConceptScore W4382775265C143998085 @default.
• W4382775265 hasConceptScore W4382775265C170493617 @default.
• W4382775265 hasConceptScore W4382775265C184235292 @default.
• W4382775265 hasConceptScore W4382775265C2776551883 @default.
• W4382775265 hasConceptScore W4382775265C2777899217 @default.
• W4382775265 hasConceptScore W4382775265C2780192828 @default.

• next